Disclaimer and safe harbor

Forward-looking statements

This presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, and “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this presentation.

Important factors that could result in such differences include but are not limited to: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, competition from other products including biosimilars, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified, nor that such product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Preclinical results also do not guarantee safe and effective performance of product candidates in humans. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may not be as safe or effective as UCB believed at the time of entering into such relationship. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this presentation. UCB expressly disclaims any obligation to update any such forward-looking statements in this presentation to reflect any change in its expectations with regard thereto or any change in events, conditions, for circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

In the event of any differences between this Presentation and the Annual or Half Year Report, the information included in the Report shall prevail.
FY 2018 information flow

Five consecutive years of profitable growth are a solid foundation for future growth

• Jean-Christophe Tellier, CEO

Promising late-stage clinical development pipeline

• Iris Loew-Friedrich, CMO

Strong financial results in 2018, updated peak sales

• Detlef Thielgen, CFO

Conclusion

• Jean-Christophe Tellier, CEO

Q&A
Five consecutive years of profitable growth are a solid foundation for future growth

Jean-Christophe Tellier, CEO
Creating Value for Patients

2018 progress towards higher patient value

From Solution to Patient

Cimzia® women of child bearing age label update
Innovative extrapolation, faster access for epilepsy patients for Briviact® (pediatric) and Keppra® + Vimpat® (China)
Evenity™ for patients living with post fracture osteoporosis approved in Japan
Midazolam nasal spray for the patients with acute repetitive seizures (ARS)
Partnership with Sciences 37 to bring clinical studies directly into patient’s home

From Patient to Science

Bimekizumab specifically and completely blocks twin cytokines driving joint and skin inflammation
UCB0107 (anti-Tau antibody) with disease modifying potential

From Science to Solution

Padsevonil to address drug-resistant epilepsy patients
Rozanolixizumab to change the treatment experience

Evenity™ for patients living with post fracture osteoporosis approved in Japan
Midazolam nasal spray for the patients with acute repetitive seizures (ARS)
Partnership with Sciences 37 to bring clinical studies directly into patient’s home
UCB is progressing on its strategic growth path

2018 achievements

Maximize core product portfolio
Cimzia®, Vimpat®, Keppra®, Briviact® + Neupro®
combined net sales: € 3.8 billion (+6%; +10% CER)

Advance development and prepare launches
Evenity® approval in Japan / under review in the U.S. & EU
Midazolam nasal spray filing in the U.S.
Bimekizumab Phase 3 program in psoriasis fully recruited

Deliver breakthrough solutions
Rozanolixizumab proof-of-concept in ITP and myasthenia gravis
Dapirolizumab pegol Phase 2b topline results in lupus
UCB0107 (anti-Tau antibody) first in human

Continued focus
Creation of Syndesi
Acquisitions of Element Genomics + midazolam nasal spray

2018 financial outlook achieved

Refer to slides in the appendix for further details
ITP: Immune thrombocytopenia
UCB, a global leader in epilepsy

20 years of R&D expertise and commercial success

- > 25,000 patients in clinical studies enrolled
- > 250 interventional epilepsy studies conducted
- > 10 epilepsy conditions studied
- New indications by innovative clinical development - extrapolation
- Neurologists stating "UCB is a leader in epilepsy": U.S. 61%; EU 82%
- 2018: ~3 million patients used Keppra®, Vimpat® or Briviact®
- Padsevonil: 1st anti epileptic drug in development with 2 mechanisms of action

Source: UCB database
UCB's sustainable performance

Fifth year of profitable growth – solid foundation for future growth

Top and bottom line growth...

... driven by product growth

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (€ million)</th>
<th>Recurring EBITDA (€ million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>3,344</td>
<td>609</td>
</tr>
<tr>
<td>2015</td>
<td>3,876</td>
<td>821</td>
</tr>
<tr>
<td>2016</td>
<td>4,147</td>
<td>1,031</td>
</tr>
<tr>
<td>2017</td>
<td>4,530</td>
<td>1,375</td>
</tr>
<tr>
<td>2018</td>
<td>4,632</td>
<td>1,398</td>
</tr>
</tbody>
</table>

- Cimzia®: 1,446
- Vimpat®: 1,099
- Keppra®: 790
- Neupro®: 321
- Briviact®: 142
UCB is progressing on its strategic growth path

Entering the "Accelerate & Expand" phase

Maximize number of lives we can impact positively
- Peak sales updates for Cimzia® and Vimpat®
- Continued growth & profitability

Bring differentiated drugs faster to patients
- Evenity™ - post fracture osteoporosis
- Cimzia® - non-radiographic axial spondyloarthritis (nr axSpA)
- Midazolam nasal spray – acute repetitive seizures

Enhance clinical development cycle times
- bimekizumab, rozanolixizumab, padsevonil, anti-Tau

Enrich our pipeline, add new patient populations
- Deliver decision points/proof-of-concept for pre-clinical and early pipeline
- Look for external opportunities

Invest in innovation, Increase profitability in 2021
- rEBITDA / revenue ratio of 31% in 2021
6 potential product launches in the next 5 years

Loss of exclusivity countered by potential upcoming product launches - subject to approvals

**Continued growth driven by core products**

- **Cimzia®** growth + expand reach to nr axSpA patients in the U.S.
- **Vimpat® & Briviact®** expand to more and more epilepsy patients
- **Keppra® & Neupro®**

**Creating value for patients**

- **Romosozumab** in post fracture osteoporosis
- **Midazolam nasal spray** in acute repetitive epilepsy seizures
- **Bimekizumab** in psoriasis, psoriatic arthritis, axial spondyloarthritis
- **Rozanolixizumab** in ITP, MG, CIDP*
- **Padsevonil** in drug-resistant epilepsy
- **Anti-Tau** in progressive supranuclear palsy (PSP)

* Immune Thrombocytopenia, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy
Strong late stage clinical development pipeline

Iris Loew-Friedrich, CMO
Increasing value of UCB's clinical pipeline

Driven by science to deliver differentiated options to patients

- **UCB0107** (Anti-Tau AB)
  - **Phase 1**
  - **Phase 2a**
    - **rozanolixizumab**
      - myasthenia gravis
      - immune thrombocytopenia
      - CIDP*
  - **Phase 2b / Phase 3 Confirmatory studies**
    - **padsevonil**
      - epilepsy
  - **Filed**
    - midazolam
      - nasal spray - acute repetitive seizures

- **UCB0599**
  - **Phase 2a**
    - **dapirolizumab pegol**
      - systemic lupus erythematosus
  - **Phase 2b / Phase 3 Confirmatory studies**
    - **bimekizumab**
      - psoriasis
      - psoriatic arthritis
      - axial spondyloarthritis
  - **Filed**
    - romosozumab
      - post fracture osteoporosis

---

*CIDP: Chronic inflammatory demyelinating polyneuropathy

Radiprodil (UCB3491) in infantile spasm was terminated due to lack of patients for recruitment – driven by sufficient standard of care

UCB6673 was returned to the partner – due to prioritization within the UCB pipeline
Increasing value of UCB's pipeline

2019 a busy and exciting year – bringing differentiated options closer to patients

2019

- **rozanolixizumab**
  - CIDP
  - Phase 2a start
- **padsevonil**
  - drug-resistant epilepsy
  - Phase 3 start
- **bimekizumab**
  - psoriatic arthritis
  - Phase 3 start
- **rozanolixizumab**
  - ITP
  - confirmatory study start

2020

- **padsevonil**
  - drug-resistant epilepsy
  - Phase 2b results
- **rozanolixizumab**
  - ITP
  - confirmatory study start
- **midazolam**
  - epilepsy
  - decision (U.S.)
- **bimekizumab**
  - axSpA
  - Phase 3 start
- **rozanolixizumab**
  - myasthenia gravis
  - confirmatory study start
- **UCB0107**
  - (anti-Tau AB)
  - Phase 1 results
- **bimekizumab**
  - psoriasis
  - Phase 3b results

CIDP: Chronic inflammatory demyelinating polyneuropathy
ITP: immune thrombocytopenia
AxSpA: axial spondyloarthritis
Evenity® (*romosozumab*) in post fracture osteoporosis

An innovative bone-forming therapy under regulatory review

- Dual effect on bone: increases bone formation **and** decreases bone resorption
- Opportunity to build new bone and slow bone loss in osteoporosis patients at imminent risk of fragility fractures
  - **ARCH, FRAME, BRIDGE** and **STRUCTURE**
    - Phase 3 studies completed
  - Under regulatory review in the United States, European Union, Australia, Canada and Switzerland
    - UCB and Amgen resubmitted Biologics License Application (BLA) to the U.S. FDA (**July 2018**)
    - **Approved in Japan** (**Jan. 2019**)

The trademark Evenity™ is provisionally approved for use by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Evenity™ (*romosozumab*) is developed in partnership with Amgen globally.
**Bimekizumab** for best efficacy in skin, joint and axial manifestations

Phase 2b programs: consistent, fast and lasting efficacy across indications

Psoriasis

- **Bimekizumab** associated with rapid and significant PASI90 response up to 12 weeks
- PASI90 response over time (NRI)
- Results presented at AAD 2018
- 60 weeks-results to be presented at AAD 2019

Psoriatic arthritis

- **Bimekizumab** associated with greater ACR50 response at Week 12 with increases up to Week 24 and maintained to Week 48
- ACR50 response rates at Week 12 and over time (NRI)
- Results presented at ACR 2018

Axial Spondyloarthritis

- **Bimekizumab** associated with greater ASAS40 response rates up to Week 12
- ASAS40 response over time (NRI)
- Results presented at EULAR 2018

<table>
<thead>
<tr>
<th>Placebo</th>
<th>Bimekizumab 160mg</th>
<th>Bimekizumab 320mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psoriasis: Note: placebo responses were zero at all time points for PASI90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Top doses shown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRI = every drop-out treated as non-responder regardless of reason for drop out</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Bimekizumab**: ambition to deliver best efficacy in skin

Psoriasis Phase 3 trials designed to demonstrate superiority

<table>
<thead>
<tr>
<th>Trial</th>
<th>NCT Number</th>
<th>Arm 1</th>
<th>Arm 2</th>
<th>Arm 3</th>
<th>Arm 4</th>
<th>Arm 5</th>
<th>Week</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BE SURE</strong></td>
<td>NCT03412747</td>
<td>bimekizumab</td>
<td>bimekizumab</td>
<td>adalimumab</td>
<td>bimekizumab</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>PS0008</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>32</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>44</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>48</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>52</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>56</td>
</tr>
<tr>
<td><strong>BE VIVID</strong></td>
<td>NCT03370133</td>
<td>placebo</td>
<td>bimekizumab</td>
<td>bimekizumab</td>
<td>ustekinumab</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>PS0009</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>32</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>44</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>48</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>52</td>
</tr>
<tr>
<td><strong>BE READY</strong></td>
<td>NCT03410992</td>
<td>placebo</td>
<td>placebo</td>
<td>bimekizumab</td>
<td>bimekizumab</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>PS0013</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>32</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>44</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>48</td>
</tr>
<tr>
<td><strong>BE RADIANT</strong></td>
<td>NCT03536884</td>
<td>bimekizumab</td>
<td>bimekizumab</td>
<td></td>
<td>secukinumab</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>PS0015</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>32</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>44</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>48</td>
</tr>
</tbody>
</table>

**Phase 3 trials**
- Primary endpoints:
  - PASI90
  - IGA 0/1
- Results Q4 2019

**Phase 3b trial**
- Primary endpoint:
  - PASI100
- Results Q3 2020

Different colors for bimekizumab indicate different dosing regimens

IGA: Investigator's Global Assessment
Bimekizumab – best in disease efficacy in skin and joints

Psoriatic arthritis Phase 3 program to start Q2 2019
– results to inform Phase 3b plans

Psoriatic arthritis

<table>
<thead>
<tr>
<th>Week</th>
<th>Bimekizumab</th>
<th>Adalimumab</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Phase 3 trials
Primary endpoint
- ACR50
Start Q2 2019

Axial SpondyloArthritis

- to deliver best efficacy in axial manifestations
- most efficient Phase 3 program - bringing it fast to patients
- Phase 3 program to start Q2 2019
Padsevonil accelerated in seamless Phase 2b / 3 program

Patients with high unmet medical need

- Novel chemical class with dual mechanism of action
- Patients having failed 4 AEDs\(^1\), ~10% of epilepsy patients

Promising signal of efficacy

**Phase 2a**

* NCT02495844 / EP0069
  55 patients
  Results presented at AES 2017

**Phase 2b**

* NCT03373383 / ARISE / EP0091
  400 patients
  Results H1 2020

**Phase 3 confirmatory study**

* NCT03739840 / DUET / EP0092
  500 patients
  Start Q1 2019 - Results H2 2021

Endpoint: seizure frequency
- from baseline over the 12-week maintenance period (U.S. and Japan)
- 75% responder rate* (EU)

---

1 AED = anti epileptic drug

International League Against Epilepsy (ILAE) definition of drug-resistant epilepsy: “failure of 2 appropriately chosen and used AED schedules (whether as monotherapies or in combination)”

2 Proportion of subjects who achieve ≥75% reduction in focal seizure frequency
**Rozanolixizumab** for patients living with IgG-mediated autoimmune disease

### Transforming disease control to the patient

Providing a patient-focused solution with a quick **home SubQ** delivery

**Transforming** disease control and ecosystem burden

**Chronic diseases with unpredictable fluctuations**

**High** treatment-associated burden (hospital setting, invasive)

#### Novel targeted approach in the treatment of IgG\(^2\) autoantibody-mediated diseases

<table>
<thead>
<tr>
<th>Condition</th>
<th>Proof of concept</th>
<th>Confirmatory phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>myasthenia gravis (MG)</td>
<td>✓</td>
<td>Start Q2 2019</td>
</tr>
<tr>
<td>immune thrombocytopenia (ITP)</td>
<td>✓</td>
<td>Start Q4 2019</td>
</tr>
<tr>
<td>CIDP(^3)</td>
<td></td>
<td>Start Q1 2019</td>
</tr>
</tbody>
</table>

---

1. SubQ: subcutaneous
2. IgG: Immunoglobulin G
3. CIDP: Chronic Inflammatory Demyelinating Polyneuropathy
Strong financial results in 2018, updated peak sales

Detlef Thielgen, CFO
2018 FY financial highlights

Core product growth drive top and bottom line

Revenue
- Net sales up by 5% (+8% CER) to € 4.4 billion driven by core products (€ 3.8 billion; +6%)

Total operating expenses
- R&D expense +10%
- R&D expense / revenue ratio of 25%

Recurring EBITDA
- Improved gross margin
- rEBITDA margin of 30.2%

Profit of the Group
- € 800 million attributable to UCB shareholders (+6%)

Core earnings per share
Based on 188 million weighted average shares outstanding
(2017: 188 million)
- € 4.78

CER: constant exchange rates

Actual
- +2%
- +6%
- +2%
- +7%
- -1%

CER
- +5%
- +8%
- +5%
- +10%
- +3%
Strong net sales growth from core products

Core products with combined € 3.8 billion (+6%)

- **Cimzia® € 1.45bn** +2% (+5%)
  - Driven by newly launched indications

- **Vimpat® € 1.1bn** +13% (+17%)
  - Strong, sustainable growth in all markets

- **Keppra® € 790m** +2% (+5%)
  - Driven by international markets, namely Japan, +13%

- **Briviact® € 142m** +63% (+70%)
  - Reaching more and more patients

- **Neupro® € 321m** +2% (+4%)
  - Reached its peak sales in 2018

- **Established brands € 514m** -7% (-10%)
  - Impacted by generic competition and divestitures

---

CER = constant currency exchange rates
1 Excluding € 100 million from hedging
5 years with profitable growth

Solid foundation enabling future growth and investment in innovation

Revenue

<table>
<thead>
<tr>
<th>Year</th>
<th>€ billion</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>3.14</td>
</tr>
<tr>
<td>2014</td>
<td>3.34</td>
</tr>
<tr>
<td>2015</td>
<td>3.88</td>
</tr>
<tr>
<td>2016</td>
<td>4.15</td>
</tr>
<tr>
<td>2017</td>
<td>4.53</td>
</tr>
<tr>
<td>2018</td>
<td>4.63</td>
</tr>
</tbody>
</table>

+8% CAGR

Recurring EBITDA

<table>
<thead>
<tr>
<th>Year</th>
<th>€ billion</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>0.54</td>
</tr>
<tr>
<td>2014</td>
<td>0.61</td>
</tr>
<tr>
<td>2015</td>
<td>0.82</td>
</tr>
<tr>
<td>2016</td>
<td>1.03</td>
</tr>
<tr>
<td>2017</td>
<td>1.38</td>
</tr>
<tr>
<td>2018</td>
<td>1.40</td>
</tr>
</tbody>
</table>

+21% CAGR
2019 and mid-term guidance

Invest in innovation, Maximize growth drivers, Return to profitability and Strengthen sustainability

2019 financial targets

- **Revenue**: €4.6 - 4.7 billion
  - Continued strong core product growth

- **rEBITDA**: 27 – 29% of revenue
  - R&D expense ratio of ~27% (+/-1% point)

- **Core EPS**: €4.40 – 4.80
  - Tax ratio of ~20%

Mid-term guidance

- **rEBITDA / revenue ratio of 31% in 2021**: UCB investing into the pipeline complemented with inorganic growth opportunities

- **Peak sales**
  - Neupro® ~ current level
  - Vimpat® ≥ €1.4 billion by 2022
  - Cimzia® ≥ €1.7 billion by 2024
  - Briviact® ≥ €600 million by 2026

rEBITDA: recurring Earnings Before Interest, Taxes, Depreciation and Amortization charge
Five consecutive years of profitable growth are a strong foundation for future growth -

Conclusion

Jean-Christophe Tellier, CEO
6 potential product launches in the next 5 years

Creating value for patients living with

- post fracture osteoporosis
- acute repetitive epilepsy seizures
- psoriasis, psoriatic arthritis or axial spondyloarthritis
- ITP, MG or CIDP*
- drug-resistant epilepsy
- progressive supranuclear palsy (PSP)

* Immune Thrombocytopenia, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy
Thank you for your attention

Your questions, please
Further facts and figures
The UCB Story – since 1928

Continuous adaptation to the changing ecosystem
Continuous track record bringing new medicines to patients

Emmanuel Janssen established Union Chimique Belge (UCB) in Brussels (Belgium), primarily focusing on industrial chemicals.

1928

1928 - Production primary care products (calcium, vitamins, insulin, etc.) during World War II

1930's - Development of a European network through acquisitions in France, Germany, Italy, Spain and the U.K.

1940's - Focus on research, resulting in the discovery in 1954 of one of the world’s first tranquillizers, Atarax®

1950's - Stronger focus on research

1960's - Globalization with acquisitions in the U.S., Korea, Thailand and Japan

1970's - Acquisition of Celltech Group Ltd, a leading British biotechnology company

1987 - Focus on biopharmaceuticals, a combination of large, antibody based molecules and small, chemically-derived molecules

1988 - Acquisition of Schwarz Pharma AG, based in Germany, bringing complementary therapeutic and geographic focus

2004 - 2008 - Divestiture of non-core business, starting with the films and chemical divisions, followed by primary care products

2004 - Focus on biopharmaceuticals, a combination of large, antibody based molecules and small, chemically-derived molecules

2006 - 2008 - Divestiture of non-core business, starting with the films and chemical divisions, followed by primary care products

2008 - Potential launches – subject to approvals

- romosozumab (U.S., EU) approved in Japan
- Cimzia® nr AxSpA (U.S.)
- midazolam nasal spray (U.S.)

The timeline is not proportionated.

nr axSpA: non-radiographic axial spondyloarthritis
UCB's patient value strategy
Sustainable company growth - Superior shareholder value

Our ambition is to be the patient preferred biopharma leader, creating patient value for specific populations through unique outcomes, the best experience and improving as many of these lives as possible. We want to be present and impact specific patient populations by 2025.

We are UCB
We are 7,495 employees focused on creating value for patients

We bring Cimzia®, Vimpat®, Keppra®, Briviact® & Neupro® to more than 3,340,000 patients

Focused on R&D:
We invest more than 20% of revenue in R&D – above industry average

We commit to reducing our ecological footprint

We reached in 2018 €4.6 billion revenue €1.4 billion recurring EBITDA, both growing the 5th year in a row
### Grow core products

#### Key information

<table>
<thead>
<tr>
<th>Cimzia®</th>
<th>Vimpat®</th>
<th>Keppra®</th>
<th>Briviact®</th>
<th>Neupro®</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Crohn’s disease (2008)</td>
<td>Epilepsy POS</td>
<td>• Epilepsy POS (1999)</td>
<td>• Epilepsy POS</td>
<td>• Parkinson’s disease</td>
</tr>
<tr>
<td>• Psoriatic arthritis (2013)</td>
<td>• Monotherapy (2014)</td>
<td>• Epilepsy myoclonic seizures</td>
<td>• Monotherapy (U.S. – 2017)</td>
<td></td>
</tr>
<tr>
<td>• Psoriasis (2018)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Astellas** (Japan - 2012)
- **Daiichi Sankyo** (Japan - 2014)
- **Otsuka** (Japan - 2008)
- **Otsuka** (Japan – 2002)

**Patients:***

- **Cimzia®**
  - > 123 000 patients, across 56 countries
  - 2024 (U.S. & EU)
  - 2026 (Japan)

- **Vimpat®**
  - > 592 000 patients, across 52 countries
  - 2022 (U.S. & EU)

- **Keppra®**
  - ≈ 2.2 million patients, across the world
  - 2008 (U.S.)
  - 2010 (EU)
  - 2020 (Japan)

- **Briviact®**
  - > 66 000 patients, across 27 countries
  - 2026 (Japan)

- **Neupro®**
  - > 371 000 patients, across 48 countries
  - 2021 (U.S. & EU)

WOCBA: women of child bearing age
PsO: psoriasis
POS: partial onset seizures, also known as focal seizures
Nr axSpA: non radiographic axial spondyloarthritis
PsA: psoriatic arthritis
GTCS: primary generalized tonic-clonic seizures
## Grow core products

### 2018 (& 2019) lifecycle management milestones

<table>
<thead>
<tr>
<th>Cimzia®</th>
<th>Vimpat®</th>
<th>Keppra®</th>
<th>Briviact®</th>
<th>Neupro®</th>
</tr>
</thead>
</table>
| • WOCBA label extension  
  (EU - Jan / U.S. - Mar / Japan - Sept)  
• Psoriasis  
  (U.S. - May / EU - June)  
• AutoClick® (Japan - Aug) | • Epilepsy POS (China - Dec)  
• Epilepsy POS pediatric (incl. dry syrup formulation - Japan - Jan 2019) | • Epilepsy GTCS (China - May)  
• Epilepsy monotherapy (China - Aug) | • Epilepsy POS: pediatric  
  (U.S. - May / EU - July) | • Parkinson’s disease  
  (China - July) |
| • Rheumatoid arthritis  
  (China - Mar)  
• Nr axSpA  
  (U.S. - Sept)  
• PsO / PsA: filing  
  (Japan – Jan 2019) | | | | |
| • Nr axSpA: Phase 3 results  
  (U.S. - May)  
• PsO / PsA: Phase 3 results (Japan - Sept) | • Epilepsy POS (China):  
  o pediatric (incl. oral formulation - Sept)  
  o IV formulation (Sept) | • Epilepsy monotherapy  
  (U.S. - Feb) | | |
| • PGTCS: Phase 3 results  
  (Q2 2019) | | | | |
| | • Acute repetitive seizures: Phase 2 results (July) | | | |
Cimzia®

continued, sustainable growth in all regions at constant exchange rates

For patients living with
- Rheumatoid arthritis
- Psoriatic arthritis
- Psoriasis
- Ankylosing spondylitis / axial spondyloarthritis
- Crohn’s disease

Net sales¹

<table>
<thead>
<tr>
<th>€ million</th>
<th>FY 2018</th>
<th>FY 2017</th>
<th>Act</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>U.S.</strong></td>
<td>896</td>
<td>918</td>
<td>-2%</td>
<td>2%</td>
</tr>
<tr>
<td><strong>Europe</strong></td>
<td>400</td>
<td>370</td>
<td>8%</td>
<td>8%</td>
</tr>
<tr>
<td><strong>International markets</strong></td>
<td>150</td>
<td>136</td>
<td>10%</td>
<td>19%</td>
</tr>
<tr>
<td><strong>Total Cimzia®</strong></td>
<td><strong>1 446</strong></td>
<td><strong>1 424</strong></td>
<td>2%</td>
<td>5%</td>
</tr>
</tbody>
</table>

2018
- ✔ Label extension to include WOCBA (EU / U.S. / Japan)
- ✔ Psoriasis: approval (U.S. & EU)
- ✔ AutoClick®: approval (Japan)
- ✔ Nr axial spondyloarthritis²: Phase 3 results & filing (U.S.)
- ✔ Psoriasis / psoriatic arthritis: Phase 3 results (Japan)

2019
- ✔ Psoriasis / psoriatic arthritis: filing (Japan)
- ✔ Nr axial spondyloarthritis²: decision (U.S.)

2024
- ✔ Loss of exclusivity (U.S. & EU)

2026
- ✔ Loss of exclusivity (Japan)

1 Numbers may not add due to rounding
CER: constant exchange rates

2 nr axSpA: non-radiographic axial spondyloarthritis
Cimzia® in-market performance

**U.S.**

- **Cimzia® vs. Rheumatology Market Growth**
  - **Cimzia® vs. Rheumatology Market Growth**
    - **Anti TNF**
    - **Biologics**
    - **Cimzia®**
  - **6.7%**

- **Cimzia® vs. RA Market**
  - **Cimzia® RA R3M Patient Share**

**Europe**

- **Cimzia® vs. Rheumatology Market Growth**
  - **Anti TNF**
  - **Biologics**
  - **Cimzia®**
  - **8.4%**

**Japan**

- **Cimzia® vs. RA Market Growth**
  - **Cimzia® RA R3M Patient Share**
  - **4.3%**

---

1 In-market growth is calculated for MAT period: US, Europe & Japan: MAT Dec 2018 vs MAT Dec 2017
2 Market share is calculated for R3M period
Vimpat®

2018 marking a new blockbuster for UCB

For patients living with
- Epilepsy – POS²
- Adults, adolescents and children from 4 years of age (EU, U.S. & Japan)

Net sales¹

<table>
<thead>
<tr>
<th>€ million</th>
<th>FY 2018</th>
<th>FY 2017</th>
<th>Act</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>822</td>
<td>746</td>
<td>10%</td>
<td>15%</td>
</tr>
<tr>
<td>Europe</td>
<td>206</td>
<td>177</td>
<td>16%</td>
<td>17%</td>
</tr>
<tr>
<td>International markets</td>
<td>70</td>
<td>53</td>
<td>33%</td>
<td>42%</td>
</tr>
<tr>
<td>Total Vimpat®</td>
<td>1099</td>
<td>976</td>
<td>13%</td>
<td>17%</td>
</tr>
</tbody>
</table>

2018
- POS: approval (China)
- POS² pediatric (incl. dry syrup formulation): filing (Japan)
- POS² pediatric (incl. oral solution): submission (China)
- IV formulation: filing (Japan & China)
- U.S. Court of Appeals confirms validity of patent

2019
- POS² pediatric: approval (Japan)
  - PGTCS³: Phase 3 results

2022
- Patent expiry (U.S. & EU)

2024
- Loss of exclusivity (Japan)

¹ Numbers may not add due to rounding
CER: constant exchange rate

2 POS: Partial-onset seizures, also known as focal seizures
3 PGTCS: Primary Generalized Tonic-Clonic Seizures
Vimpat® in-market performance

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.
Reflecting both, the established brand and the maturity

**Net sales**

<table>
<thead>
<tr>
<th>€ million</th>
<th>FY 2018</th>
<th>FY 2017</th>
<th>Act</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>221</td>
<td>232</td>
<td>-5%</td>
<td>0%</td>
</tr>
<tr>
<td>Europe</td>
<td>216</td>
<td>235</td>
<td>-8%</td>
<td>-8%</td>
</tr>
<tr>
<td>International markets</td>
<td>352</td>
<td>311</td>
<td>13%</td>
<td>19%</td>
</tr>
<tr>
<td>Total Keppra®</td>
<td>790</td>
<td>778</td>
<td>2%</td>
<td>5%</td>
</tr>
</tbody>
</table>

For patients living with
- Epilepsy – POS
- Epilepsy – PGTCS
- Epilepsy myoclonic seizures

2018
- Epilepsy GTCS: approval (China)
- Epilepsy monotherapy: approval (China)

2019
- Epilepsy monotherapy: filing (U.S.)

2020
- Patent expiry (Japan)

1 Numbers may not add due to rounding

CER: constant exchange rate

POS: Partial-onset seizures, also known as focal seizures
PGTCS: Primary Generalized Tonic-Clonic Seizures
GTCS: Generalized Tonic-Clonic Seizures
Keppra® in-market performance

**U.S.**

Keppra® vs. AED Market Growth (TRx)

-12.7%

-11.5%

Keppra® – R3M TRx Share

-0.1%

0.7%

**Europe**

Keppra® vs. AED Market Growth (TDx)

-4.1%

-1.5%

-5.6%

Keppra® – R3M TDx Share

12.2%

-0.2%

**Japan**

Keppra® vs. AED Market Growth (TDx)

6.6%

+11.7%

18.3%

Keppra® – R3M TDx Share

17.2%

Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx

Source data EU: IMS MIDAS - In-Market KPIs are based on TDx

Source data JP: IMS MIDAS - In-market KPIs are based on TDx

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.
## Available to more and more patients

For patients living with
- Epilepsy – POS²
- Adults, adolescents and children from 4 years of age (EU & U.S.)

### Net sales¹

<table>
<thead>
<tr>
<th></th>
<th>FY 2018</th>
<th>FY 2017</th>
<th>Act</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>U.S.</strong></td>
<td>109</td>
<td>63</td>
<td>72%</td>
<td>80%</td>
</tr>
<tr>
<td><strong>Europe</strong></td>
<td>29</td>
<td>22</td>
<td>32%</td>
<td>33%</td>
</tr>
<tr>
<td><strong>International markets</strong></td>
<td>4</td>
<td>1</td>
<td>&gt;100%</td>
<td>&gt;100%</td>
</tr>
<tr>
<td><strong>Total Briviact®</strong></td>
<td>142</td>
<td>87</td>
<td>63%</td>
<td>70%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>✔️ POS²: pediatric approval (U.S. &amp; EU)</td>
</tr>
<tr>
<td>2021</td>
<td>✳️ Acute repetitive seizures: Phase 2 results</td>
</tr>
<tr>
<td>2026</td>
<td>✳️ Patent expiry (U.S. &amp; EU)</td>
</tr>
</tbody>
</table>

---

¹ Numbers may not add due to rounding

² POS: Partial-onset seizures, also known as focal seizures

Acute repetitive seizures study NCT03021018 – presented at AES 2018
Briviact® in-market performance

A new therapeutic option in the AED market

---

**U.S.**

**Briviact® – R3M TRx Share**

- Dec-17: 0.00%
- Mar-18: 0.10%
- Jun-18: 0.30%
- Sep-18: 0.40%
- Dec-18: 0.50%

Source data U.S.: U.S. IMS NPA
In-Market KPIs are based on TRx

**Europe**

**Briviact® – R3M TDx Share**

- Dec-17: 0.00%
- Mar-18: 0.30%
- Jun-18: 0.50%
- Sep-18: 0.70%
- Dec-18: 0.80%

Source data EU: IMS MIDAS
In-Market KPI’s are based on TDx

---

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In EU, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.
### Net sales<br>€ million

<table>
<thead>
<tr>
<th></th>
<th>FY 2018</th>
<th>FY 2017</th>
<th>Act</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>U.S.</strong></td>
<td>101</td>
<td>96</td>
<td>5%</td>
<td>10%</td>
</tr>
<tr>
<td><strong>Europe</strong></td>
<td>174</td>
<td>168</td>
<td>3%</td>
<td>4%</td>
</tr>
<tr>
<td><strong>International markets</strong></td>
<td>46</td>
<td>50</td>
<td>-7%</td>
<td>-4%</td>
</tr>
<tr>
<td><strong>Total Neupro®</strong></td>
<td>321</td>
<td>314</td>
<td>2%</td>
<td>4%</td>
</tr>
</tbody>
</table>

1 Numbers may not add due to rounding<br>CER: constant exchange rate

For patients living with
• Parkinson’s disease
• Restless legs syndrome

2018
- Parkinson’s disease: approval (China)

2021
- Patent expiry (U.S. & EU)

2024
- Patent expiry (Japan)
Neupro® in-market performance

**U.S.**

Neupro® PD vs. PD (KC)

- Market Growth (TRx)
  - PD market: 0.8%
  - PD key competitors: 0.8%
  - Neupro®: -4.3%

- Neupro® PD – R3M TRx Share
  - Dec-17: 6.3%
  - Dec-18: 0.8%

Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx

**Europe**

Neupro® PD vs. PD (KC)

- Market Growth (TDx)
  - PD Market: 2.5%
  - PD key competitors: 1.2%
  - Neupro®: 3.6%

- Neupro® PD – R3M TDx Share
  - Dec-17: 15.9%
  - Dec-18: +0.1%

Source data EU: IMS MIDAS - In-Market KPI’s are based on TDx

**Japan**

Neupro® PD vs. PD (KC)

- Market Growth (TDx)
  - PD Market: 0%
  - PD key competitors: 0%
  - Neupro®: 21.0%

- Neupro® PD – R3M TDx Share
  - Dec-17: 25.0%
  - Dec-18: +6.3%

Source data JP: IMS MIDAS - In-market KPI's are based on TDx

---

PD market: All molecules in ATC3= N4A. In the Europe and Japan, the TDx of all these molecules are factored for PD usage. In the US, only the TRx of Rotigotine, Pramipexole and Ropinirole are factored for PD usage.

PD Key Competitors (KC) market: The 8 DA’s (Dopamine Antagonists): Bromocriptine, Cabergoline, Lisuride, Pergolide, Rotigotine, Pramipexole, Piribedil, Ropinirole.

In the U.S., only Rotigotine, Pramipexole and Ropinirole are factored for PD usage, hence the PD market and PD KC market are the same.
Translating scientific hypotheses into clinical development

**Evenity™ (romosozumab)**
- post fracture osteoporosis

**midazolam nasal spray**
- acute repetitive seizures

**bimekizumab (IL17A/F)**
- psoriasis
- psoriatic arthritis
- axial spondyloarthritis

**dapirolizumab pegol (CD40L antibody)**
- systemic lupus erythematosus

**padsevonil (PPSI)**
- drug-resistant epilepsy

**rozanolixizumab (FcRn)**
- myasthenia gravis
- immune thrombocytopenia
- CIDP*

**UCB7858 UCB0159 UCB0599 UCB0107**

*partner: Amgen
*approved in Japan

Radiprodil (UCB3491) in infantile spasm was terminated due to lack of patients for recruitment – driven by sufficient standard of care
UCB6673 was returned to the partner – due to prioritization within the UCB pipeline

Evenity™ is the trade name of romosozumab which has been provisionally approved by the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA).

*CIDP: Chronic Inflammatory Demyelinating Polyneuropathy
Translating **scientific hypotheses** into clinical differentiation

**Dual blockade of IL-17F and IL-17A by *bimekizumab***

IL-17F and IL-17A are **twin cytokines** driving joint and skin inflammation

Dual blockade of IL-17F on top of IL-17A will improve therapeutic efficacy versus targeting IL-17A alone

*Bimekizumab* specifically and completely blocks IL-17F and IL-17A
### Bimekizumab Phase 3 development program in psoriasis

3 / 4 trials against active comparators - designed to demonstrate superiority

| Phase 3 | BE VIVID / PS0009  
NCT03370133 | BE SURE / PS0008  
NCT03412747 | BE READY / PS0013  
NCT03410992 | BE RADIANT / PS0015  
NCT03536884 |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Duration</strong></td>
<td>• 52 weeks</td>
<td>• 56 weeks</td>
<td>• 56 weeks</td>
<td>• 48 weeks</td>
</tr>
</tbody>
</table>
| **Comparator** | • ustekinumab  
• placebo | • adalimumab  
• placebo | • placebo  
• PASI90 response  
• IGA 0/1 response | • secukinumab  
• PASI100 response |
| **Primary endpoints @ week 16** | • PASI90 response  
• IGA 0/1 response | • PASI90 response  
• IGA 0/1 response | • PASI90 response  
• IGA 0/1 response | • PASI100 response |
| **Start** | Start Dec. 2017  
Results: Q4 2019 | Start Jan. 2018  
Results: Q4 2019 | Start Feb. 2018  
Results: Q4 2019 | Start June 2018  
Results: Q3 2020 |

1 moderate to severe chronic plaque psoriasis  
PASI90: Patients experiencing at least 90% skin clearance  
PASI100: Patients experiencing 100% skin clearance

IGA: Investigator’s Global Assessment  
Source: www.clinicaltrial.gov
### Padsevonil Phase 2 program in drug-resistant focal epilepsy

**Patients with high unmet medical need**

#### Phase 2a
**EP0069 / NCT02495844**
- **55 patients** with highly drug-resistant focal epilepsy
  - failed with ≥4 AED
  - experiencing ≥4 seizures / week
- **Comparator**
  - *padsevonil / placebo (2 arms)*
- **Endpoints**
  - 75% responder rate*
    - **31% padsevonil**
    - 11% placebo

#### Phase 2b
**ARISE / EP0091 / NCT03373383**
- **400 patients** with drug-resistant focal epilepsy
  - failed with ≥ 4 AED
  - experiencing ≥4 seizures / month
- **Comparator**
  - *padsevonil / placebo (5 arms)*
- **Endpoints**
  - Seizure frequency
    - from baseline over the 12 week maintenance period (U.S., Japan)
    - 75% responder rate* (EU)

#### Phase 3
**DUET / EP0092 / NCT03739840**
- **500 patients** with drug-resistant focal epilepsy
  - failed with ≥ 4 AED
  - experiencing ≥4 seizures / month
- **Comparator**
  - *padsevonil / placebo (4 arms)*
- **Endpoints**
  - Seizure frequency
    - from baseline over the 12 week maintenance period (U.S., Japan)
    - 75% responder rate* (EU)

* Proportion of subjects who achieve ≥75% reduction in focal seizure frequency

---

**AES 2017**

**Results H1 2020**

**Start Q1 2019**
### Rozanolixizumab potential in multiple IgG autoantibody-mediated diseases with high unmet medical need

<table>
<thead>
<tr>
<th>Condition</th>
<th>Myasthenia gravis</th>
<th>Immune thrombocytopenia</th>
<th>Chronic inflammatory demyelinating polyneuropathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Antibodies target components of neuromuscular junction</td>
<td>• Antibodies target platelets and destroy them</td>
<td>• Antibodies target components of peripheral nerves, causing damage to the myelin sheath and axon</td>
<td></td>
</tr>
<tr>
<td>• Muscle weakness (extremities, eyes, bulbar and respiratory symptoms)</td>
<td>• Thrombocytopenia</td>
<td>• Motor deficits</td>
<td></td>
</tr>
<tr>
<td>• Fatigue</td>
<td>• Bleeding (Petechiae, Purpura, Nosebleeds, intracranial bleeding)</td>
<td>• Sensory deficits</td>
<td></td>
</tr>
<tr>
<td>• ~ 10 - 45 cases / 100 000</td>
<td>• Fatigue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Surgery (thymectomy)</td>
<td>• Platelet transfusion</td>
<td></td>
<td>• IV Steroids</td>
</tr>
<tr>
<td>• Steroids, steroid-sparing drugs</td>
<td>• IV immunoglobulin (IVIg)</td>
<td></td>
<td>• IV / subQ immunoglobulin</td>
</tr>
<tr>
<td>• Plasma exchange (PEX)</td>
<td>• Steroids</td>
<td></td>
<td>• Plasma exchange (PEX)</td>
</tr>
<tr>
<td>• IV immunoglobulin (IVIg)</td>
<td>• Surgery (splenectomy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• TPO receptor agonists</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Current therapies associated with morbidity and burdensome to patients & healthcare systems

**IV:** Intravenous; **subQ:** sub-cutaneous; **TPO:** thrombopoietin
Rozanolixizumab SubQ treatment for IgG-mediated diseases

Proof of concept established in MG & ITP
Moving to confirmatory phase

### CIDP\(^1\)
- **34 patients** with Chronic Inflammatory Demyelinating Polyneuropathy
- **Duration**: 12 weeks
- **Comparator**: placebo (2 arms)
- **Endpoints**: Clinical change from baseline
- **Safety and tolerability**
- **Proof of concept study to start Q1 2019**

### Myasthenia gravis
- **43 patients** with moderate to severe MG
  - Diagnosis of MG @ screening
  - Be considered for treatment with immunological therapy
- **Duration**: 99 days
- **Comparator**: placebo (2 arms)
- **Endpoints**:
  - Change from baseline in:
    - Quantitative Myasthenia Gravis (QMG) score to visit 9 (day 29)
    - Myasthenia Gravis-Composite score to Visit 9
    - Myasthenia Gravis-Activities of Daily Living (MGADL) score to Visit 9
- **Proof of concept achieved**
  - Confirmatory phase to start Q2 2019

### Immune thrombocytopenia
- **66 patients** with primary ITP
  - ≥ 3 months diagnosis @ screening
  - Platelet count <30x10^9/L @ screening and <35x10^9/L @ baseline
- **Duration**: 12 weeks
- **Comparator**: 5 arms
- **Endpoints**: Subjects experiencing at least one Treatment Emergent Event (TEAE) during the study
- **Confirmatory phase to start Q4 2019**

---

\(^1\) CIDP: Chronic Inflammatory Demyelinating Polyneuropathy

---

**Note:**
- **CIDP**: subQ: sub-cutaneous
- **IgG**: immunoglobulin

---
Phase 1 - UCB0107, an anti-Tau antibody for Progressive Supranuclear Palsy & Alzheimer’s disease

**Key facts**

UCB0107 blocks tau uptake and aggregation

- Tau misfolding and aggregation leads to neuronal death and disease spread

- PSP is a rare, rapidly progressing tauopathy with debilitating cognitive & motor symptoms

- Alzheimer’s Disease is also a tauopathy, with high prevalence and economic impact

**Key insights**

UCB0107 was generated to block spreading of tau seeds from patient materials

Tau seeds spread from dying cells to infect other neurons

Source: UCB internal data

AD: Alzheimer’s disease

PSP: Progressive Supranuclear Palsy
# Recurring EBITDA

<table>
<thead>
<tr>
<th>€ million</th>
<th>ACTUAL</th>
<th>VARIANCE</th>
<th>ACTUAL RATES</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>4 632</td>
<td>4 530</td>
<td>2%</td>
<td>5%</td>
</tr>
<tr>
<td>Net sales</td>
<td>4 412</td>
<td>4 182</td>
<td>5%</td>
<td>8%</td>
</tr>
<tr>
<td>Royalty income and fees</td>
<td>92</td>
<td>108</td>
<td>-15%</td>
<td>-11%</td>
</tr>
<tr>
<td>Other revenue</td>
<td>128</td>
<td>240</td>
<td>-47%</td>
<td>-46%</td>
</tr>
<tr>
<td><strong>Gross Profit</strong></td>
<td>3 434</td>
<td>3 330</td>
<td>3%</td>
<td>6%</td>
</tr>
<tr>
<td>Marketing and selling expenses</td>
<td>- 964</td>
<td>- 940</td>
<td>3%</td>
<td>6%</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>-1 161</td>
<td>-1 057</td>
<td>10%</td>
<td>11%</td>
</tr>
<tr>
<td>General and administrative expenses</td>
<td>- 180</td>
<td>- 192</td>
<td>-6%</td>
<td>-5%</td>
</tr>
<tr>
<td>Other operating income/expenses (-)</td>
<td>- 24</td>
<td>- 11</td>
<td>&gt;100%</td>
<td>&gt;100%</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>-2 329</td>
<td>-2 200</td>
<td>6%</td>
<td>8%</td>
</tr>
<tr>
<td><strong>Recurring EBITDA (rEBITDA)</strong></td>
<td>1 105</td>
<td>1 130</td>
<td>-2%</td>
<td>1%</td>
</tr>
<tr>
<td>Add: Amortization of intangible assets</td>
<td>170</td>
<td>160</td>
<td>6%</td>
<td>8%</td>
</tr>
<tr>
<td>Add: Depreciation charges</td>
<td>123</td>
<td>85</td>
<td>44%</td>
<td>47%</td>
</tr>
<tr>
<td><strong>Recurring EBITDA (rEBITDA)</strong></td>
<td>1 398</td>
<td>1 375</td>
<td>2%</td>
<td>5%</td>
</tr>
</tbody>
</table>

**CER**: constant exchange rate  
**EBIT**: Earnings before interest and taxes  
**EBITDA**: Earning before interests, taxes, depreciation and amortization charges
## 2018 profit

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
<th>ACTUAL RATES</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recurring EBIT</strong></td>
<td>1,105</td>
<td>1,130</td>
<td>-2%</td>
<td>1%</td>
</tr>
<tr>
<td>Impairment charges</td>
<td>0</td>
<td>-1</td>
<td>-74%</td>
<td>-69%</td>
</tr>
<tr>
<td>Restructuring expenses</td>
<td>-20</td>
<td>-23</td>
<td>-11%</td>
<td>-10%</td>
</tr>
<tr>
<td>Gain on disposals</td>
<td>47</td>
<td>3</td>
<td>&gt;100%</td>
<td>&gt;100%</td>
</tr>
<tr>
<td>Other non recurring income/expenses</td>
<td>-23</td>
<td>-22</td>
<td>6%</td>
<td>7%</td>
</tr>
<tr>
<td><strong>Total non recurring income/expenses (-)</strong></td>
<td>4</td>
<td>-43</td>
<td>&gt;-100%</td>
<td>&gt;-100%</td>
</tr>
<tr>
<td><strong>EBIT (operating profit)</strong></td>
<td>1,109</td>
<td>1,087</td>
<td>2%</td>
<td>5%</td>
</tr>
<tr>
<td>Net financial expenses (-)</td>
<td>-93</td>
<td>-99</td>
<td>-6%</td>
<td>-5%</td>
</tr>
<tr>
<td>Result from associates</td>
<td>-1</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Profit before income taxes</strong></td>
<td>1,015</td>
<td>988</td>
<td>3%</td>
<td>6%</td>
</tr>
<tr>
<td><strong>Income tax expenses</strong></td>
<td>-200</td>
<td>-218</td>
<td>-8%</td>
<td>-5%</td>
</tr>
<tr>
<td><strong>Profit from continuing operations</strong></td>
<td>815</td>
<td>770</td>
<td>6%</td>
<td>9%</td>
</tr>
<tr>
<td>Profit/loss (-) from discontinued operations</td>
<td>8</td>
<td>1</td>
<td>&gt;100%</td>
<td>&gt;100%</td>
</tr>
<tr>
<td><strong>Profit</strong></td>
<td>823</td>
<td>771</td>
<td>7%</td>
<td>10%</td>
</tr>
<tr>
<td>Attributable to UCB shareholders</td>
<td>800</td>
<td>753</td>
<td>6%</td>
<td>10%</td>
</tr>
<tr>
<td>Attributable to non-controlling interests</td>
<td>23</td>
<td>18</td>
<td>26%</td>
<td>32%</td>
</tr>
<tr>
<td><strong>Profit attributable to UCB shareholders</strong></td>
<td>800</td>
<td>753</td>
<td>6%</td>
<td>10%</td>
</tr>
</tbody>
</table>

CER: constant exchange rate  
EBIT: Earnings before interest and taxes
## Core earnings per share

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
<th>ACTUAL RATES</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Profit</td>
<td>823</td>
<td>771</td>
<td>7%</td>
<td>10%</td>
</tr>
<tr>
<td>Attributable to UCB shareholders</td>
<td>800</td>
<td>753</td>
<td>6%</td>
<td>10%</td>
</tr>
<tr>
<td>Attributable to non-controlling interests</td>
<td>23</td>
<td>18</td>
<td>26%</td>
<td>32%</td>
</tr>
<tr>
<td>Profit attributable to UCB shareholders</td>
<td>800</td>
<td>753</td>
<td>6%</td>
<td>10%</td>
</tr>
<tr>
<td>Total non-recurring income (-)/expenses</td>
<td>- 4</td>
<td>43</td>
<td>&gt;-100%</td>
<td>&gt;-100%</td>
</tr>
<tr>
<td>Income tax on non-recurring expenses (-)/ credit</td>
<td>7</td>
<td>12</td>
<td>-43%</td>
<td>-43%</td>
</tr>
<tr>
<td>Financial one-off income (-)/expenses</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Income tax on financial one-off income/expenses (-)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Profit (-)/loss from discontinued operations</td>
<td>- 8</td>
<td>- 1</td>
<td>&gt;100%</td>
<td>&gt;100%</td>
</tr>
<tr>
<td>Amortization of intangibles linked to sales</td>
<td>134</td>
<td>125</td>
<td>8%</td>
<td>9%</td>
</tr>
<tr>
<td>Income tax on amortization of intangibles linked to sales</td>
<td>- 28</td>
<td>- 25</td>
<td>11%</td>
<td>11%</td>
</tr>
<tr>
<td>Core profit attributable to UCB shareholders</td>
<td>901</td>
<td>907</td>
<td>-1%</td>
<td>3%</td>
</tr>
<tr>
<td>Weighted average number of shares (million)</td>
<td>188</td>
<td>188</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>Core EPS attributable to UCB shareholders (€)</td>
<td>4.78</td>
<td>4.82</td>
<td>-1%</td>
<td>3%</td>
</tr>
</tbody>
</table>

**Strong growth of core net profit**
### 2018 Key Product Net Sales Performance

<table>
<thead>
<tr>
<th></th>
<th>Actual (€ million)</th>
<th>2018</th>
<th>2017</th>
<th>Actual Rates</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immunology/Cimzia®</strong></td>
<td>1 446</td>
<td>1 424</td>
<td></td>
<td>2%</td>
<td>5%</td>
</tr>
<tr>
<td><strong>Neurology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vimpat®</td>
<td>1 099</td>
<td>976</td>
<td></td>
<td>13%</td>
<td>17%</td>
</tr>
<tr>
<td>Keppra® (including Keppra® XR / E)</td>
<td>790</td>
<td>778</td>
<td></td>
<td>2%</td>
<td>5%</td>
</tr>
<tr>
<td>Neupro®</td>
<td>321</td>
<td>314</td>
<td></td>
<td>2%</td>
<td>4%</td>
</tr>
<tr>
<td>Briviact®</td>
<td>142</td>
<td>87</td>
<td></td>
<td>63%</td>
<td>70%</td>
</tr>
<tr>
<td><strong>Established brands</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zyrtec® (including Zyrtec-D/Cirrus®)</td>
<td>101</td>
<td>103</td>
<td></td>
<td>-2%</td>
<td>2%</td>
</tr>
<tr>
<td>Xyzal®</td>
<td>90</td>
<td>104</td>
<td></td>
<td>-14%</td>
<td>-11%</td>
</tr>
<tr>
<td>Other products</td>
<td>323</td>
<td>368</td>
<td></td>
<td>-12%</td>
<td>-9%</td>
</tr>
<tr>
<td><strong>Net sales before hedging</strong></td>
<td>4 312</td>
<td>4 154</td>
<td></td>
<td>4%</td>
<td>8%</td>
</tr>
<tr>
<td><strong>Designated hedges reclassified to net sales</strong></td>
<td>100</td>
<td>28</td>
<td></td>
<td>&gt;100%</td>
<td></td>
</tr>
<tr>
<td><strong>Total net sales</strong></td>
<td>4 412</td>
<td>4 182</td>
<td></td>
<td>5%</td>
<td>8%</td>
</tr>
</tbody>
</table>

Numbers may not add due to rounding
CER: constant exchange rate
Strong Cash Flows

"Net debt/rEBITDA ratio of 1:1"

CAGR: composite annual growth rate

CAGR: 32.7%

Cash flow from continuing operations

Net debt & recurring EBITDA ratio

* KU rEBITDA prior to KU divestment added back
One UCB today: A global player

Presence in 38 countries complemented by a robust network of partners

49/51 Women/Men

7 495 UCB employees world-wide

33% joined in the last 2Y
36% have worked 3-10Y
32% have worked for >10Y

7% below 30Y
67% between 30–49Y
26% over 50Y

1 105 New colleagues joined

Situation at December 2018
Green strategy @ UCB

UCB environmental commitments by 2030

- CO₂ emissions -35%
- Water consumption -20%
- Waste production -25%

Corporate governance

Board of Directors

- 13 members
  - Mandate: 4 year
  - Age limit: 70
- 4 women (31%)
- 7 independent directors (54%)
- 5 nationalities

Status at 31 December 2018
Corporate governance

Executive Committee

• 12 members
  • JC Tellier CEO since 2015
• 3 women (25%)
• 6 nationalities
Stable shareholder base with free-float of 62%

Weighted average shares outstanding in 2018: 188 million

Source: Latest notifications, FactSet and UCB underlying ownership analysis (October 2018)
Your UCB Investor Relations team

Antje Witte, Vice President Investor Relations
Phone: +32 2 559 9414
E-mail: antje.witte@ucb.com

Isabelle Ghellynck, Assoc. Director Investor Relations
Phone: +32 2 559 9588
E-mail: isabelle.ghellynck@ucb.com

Nathalie Deldime, Investor Relations Events Manager
Phone: +32 2 559 9291
E-mail: nathalie.deldime@ucb.com

Check out our IR App & stay tuned to UCB wherever you go!